Prescriber Scope of Practice for Anxiety in Texas

If you’re a psychiatrist or PMHNP treating anxiety disorders via telehealth, you know that managing medications isn’t just about clinical decisions—it’s navigating a maze of federal DEA rules and state-specific prescribing laws. And right now, that maze is shifting.

Here’s the reality: federal telemedicine prescribing rules for controlled substances are still temporary, extended through December 31, 2025. That means the ability to prescribe benzodiazepines or other anxiolytics via telehealth without an in-person visit could change in 2026. Meanwhile, every state has its own layer of requirements—from PDMP checks to NP practice authority limits—that directly impact how you can treat anxiety patients across state lines.

This guide breaks down what you need to know about prescribing anxiety medications in 2026: the DEA rules keeping telehealth prescribing alive (for now), how psychiatrists’ and PMHNPs’ scope of practice differs by state, and the specific regulations in six high-volume states: California, Texas, Florida, New York, Pennsylvania, and Illinois.

Why Anxiety Prescribing Regulations Matter to Your Practice

Most anxiety medications fall into two categories: non-controlled (SSRIs, SNRIs, buspirone) and controlled substances (primarily benzodiazepines like Xanax, Ativan, and Klonopin—all Schedule IV). The non-controlled medications? Straightforward. The controlled ones? That’s where federal and state regulations intersect and create compliance headaches.

The federal baseline: The Ryan Haight Act normally requires an in-person medical evaluation before prescribing any controlled substance via telemedicine. But COVID-era public health emergency waivers suspended that requirement, and the DEA has now extended those flexibilities three times—most recently through the end of 2025.

The state overlay: Even with federal permission to prescribe controlled substances via telehealth, you still must comply with your state’s:

• Licensing requirements (you need a license in every state where your patients are located)
• Prescription Drug Monitoring Program (PDMP) mandates
• E-prescribing requirements
• Scope of practice rules (especially critical for PMHNPs)
• Telehealth-specific prescribing restrictions

Miss any of these, and you’re practicing outside the law—even if your clinical care is excellent.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Federal DEA Rules: The Temporary Reality of Telehealth Controlled Substance Prescribing

Let’s start with what the DEA currently allows and what might change.

Current Rules (Through December 31, 2025)

As of February 2026, DEA-registered practitioners can prescribe Schedule II–V controlled substances via telemedicine without requiring an initial in-person examination. This includes:

• Benzodiazepines (Schedule IV) like alprazolam, clonazepam, lorazepam
• Schedule II stimulants (if treating comorbid ADHD)
• Other anxiolytics or sedatives as clinically appropriate

What you must do:

• Conduct a proper evaluation via live audio-video (no text-only assessments)
• Document the encounter as a telemedicine visit
• Comply with all state laws, including PDMP checks
• Issue prescriptions via DEA-compliant e-prescribing systems
• Maintain your DEA registration and any required state controlled substance licenses

This flexibility exists because the DEA, working with HHS, extended the COVID-era public health emergency exception for the third time in November 2024. It’s a bridge policy while the DEA reconsiders permanent telemedicine prescribing rules.

What Almost Happened (and Could Still Happen)

In early 2023, the DEA proposed reinstating the in-person visit requirement, with a limited 30-day telehealth prescribing allowance for certain controlled substances. The proposal drew over 38,000 public comments—mostly from mental health providers, patients, and advocacy groups arguing it would devastate access to care.

The DEA pulled back and extended the temporary rules instead. But permanent regulations are still coming. Expect the DEA to issue final rules sometime in 2025 or 2026 that could:

• Require an in-person exam within a certain timeframe (e.g., 30 days) for ongoing controlled substance prescribing
• Create a special DEA telemedicine registration allowing remote prescribing under specific conditions
• Maintain current flexibilities for certain medications or patient populations

Bottom line for providers: The current system works, but it’s temporary. If you’re building a telehealth anxiety practice, have a contingency plan for potential in-person exam requirements, whether through affiliate clinics, hybrid care models, or partnerships with local providers.

Psychiatrists’ Scope of Practice: Full Authority, State-Specific Requirements

If you’re a psychiatrist (MD or DO), your scope of practice for anxiety treatment is the broadest in mental healthcare. Every state authorizes you to independently:

• Diagnose any anxiety disorder
• Prescribe any medication, including all controlled substances
• Provide psychotherapy or medication management
• Practice via telehealth to patients in states where you’re licensed

No supervision required. No formulary restrictions. No collaborative agreements.

The regulatory considerations are administrative:

Multi-State Licensing

You must hold a valid medical license in every state where your patients are located. You cannot treat a Texas patient via telehealth with only a California license—that’s practicing medicine without a license, and state medical boards take it seriously.

Interstate Medical Licensure Compact (IMLC) can help: Texas, Illinois, Pennsylvania, and Florida are members, allowing streamlined licensing for qualified physicians. California and New York are not in the IMLC, requiring full individual applications.

Prescription Drug Monitoring Programs (PDMPs)

Almost every state mandates checking the PDMP before prescribing controlled substances. For example:

• New York: Must check the I-STOP registry before every Schedule II–IV prescription (including benzodiazepines)
• California: Must check CURES within 24 hours of initial controlled prescription and at least every 4 months for ongoing therapy
• Florida: Must check E-FORCSE before prescribing any Schedule II–V drug and every 90 days for continuation
• Pennsylvania: Must check before initial opioid or benzodiazepine prescription and each refill
• Texas: Mandatory check for opioids, benzos, barbiturates, and carisoprodol

Most EHRs now integrate PDMP queries, but you’re responsible for compliance. State boards audit prescribers, and failure to check can trigger disciplinary action.

E-Prescribing Requirements

California and New York mandate e-prescribing for all medications. Most other states require or strongly encourage it for controlled substances. You’ll need a DEA-compliant Electronic Prescribing of Controlled Substances (EPCS) system with two-factor authentication.

Paper prescriptions for controlled substances are essentially obsolete in telehealth practice—and in states like Florida, require special tamper-proof prescription pads that make them impractical for remote care.

DEA Registration and State Controlled Substance Licenses

Your DEA registration must be current and in the state where you’re practicing. Some states (Illinois, Florida) also require a separate state controlled substance license in addition to your DEA number.

Key point: If you’re treating patients in multiple states via a platform like Klarity, you need DEA registration in each state—not just your home state. This is often overlooked by providers new to multi-state telehealth.

PMHNPs’ Scope of Practice: State-by-State Variation in Autonomy and Prescribing

Psychiatric Mental Health Nurse Practitioners are critical to addressing the provider shortage in anxiety treatment—but your scope of practice depends heavily on which state you’re in.

All PMHNPs can diagnose and treat anxiety disorders. The differences lie in:

1. Practice authority (independent vs. physician supervision)
2. Controlled substance prescribing limits (especially Schedule II)

Independent Practice States (Full or Near-Full Authority)

New York: PMHNPs with 3,600+ hours of practice can practice independently—no physician collaboration required. This became permanent law in 2022. You can evaluate, diagnose, and prescribe (including controlled substances) under your own authority.

Illinois: PMHNPs who complete 4,000 hours of experience and additional training can apply for Full Practice Authority. Once granted, you can prescribe Schedule III–V independently. Schedule II narcotics (opioids) require a physician consultation relationship for the first 5 years of FPA. For anxiety medications (which are typically Schedule IV benzos), you have full independence.

California: In transition. AB 890 created pathways for NP independence starting in 2023 (in certain settings), with full independence across all settings available by January 2026. If you meet the experience requirements (3+ years), you’ll soon be able to practice and prescribe anxiety medications without physician protocols.

Restricted Practice States (Physician Collaboration Required)

Texas: You must work under a Prescriptive Authority Agreement (PAA) with a physician. Critical limitation: Texas APRNs cannot prescribe Schedule II controlled substances in outpatient settings—only in hospitals, emergency departments, or hospice care. For anxiety treatment, this typically doesn’t matter (most anxiety meds are Schedule IV), but if you’re treating comorbid ADHD, the physician must prescribe stimulants.

Florida: You must have a supervisory protocol with a physician (often a psychiatrist). Florida has a unique rule for controlled substances: NPs can only prescribe Schedule II drugs for a 7-day supply maximum unless you’re a ‘psychiatric nurse’ (certified PMHNP) treating a mental health condition—then the 7-day limit doesn’t apply. This carve-out allows psychiatric NPs more flexibility for medications like ADHD stimulants, but most anxiety treatment uses Schedule IV benzos anyway.

Pennsylvania: You need a collaborative agreement with a physician. The agreement must specify prescriptive authority. Pennsylvania law limits NPs to:

• Schedule II: 30-day supply maximum (physician must be notified within 24 hours)
• Schedule III–IV: 90-day supply maximum

So a PA PMHNP can prescribe a 90-day supply of Klonopin, but the collaborative agreement must explicitly authorize it.

Controlled Substance Prescribing: What You Can and Can’t Do

Schedule IV benzodiazepines (the mainstay of acute anxiety pharmacotherapy) are generally prescribable by PMHNPs in all states with appropriate authority. The differences:

• Independent states: You prescribe under your own DEA number
• Collaborative states: You may need the physician’s name on the prescription or documented approval in your protocol

Schedule II drugs (stimulants for ADHD, certain sedatives) have more restrictions:

• Texas bans outpatient NP prescribing entirely
• Florida limits to 7 days unless you’re a psychiatric specialist treating mental illness
• Pennsylvania allows 30-day supplies under collaboration
• New York and California allow with proper authority

Practical impact: If you’re treating anxiety with comorbid ADHD via telehealth, know your state’s Schedule II rules. In restrictive states, you’ll need a physician to prescribe stimulants or the platform you work with (like Klarity) will have MD coverage.

PDMP Requirements Apply to PMHNPs Too

All the PDMP mandates for physicians apply equally to nurse practitioners. You must check your state’s monitoring program before prescribing controlled substances and follow the same documentation requirements.

State-Specific Regulations: What You Need to Know in Six High-Volume States

California

For Psychiatrists:

• No special telehealth license; must have full CA medical license (CA is not in IMLC)
• Can establish patients and prescribe via telehealth without in-person exam if standard of care met
• Must check CURES PDMP at least every 4 months for Schedule II–IV prescriptions
• E-prescribing mandatory for all prescriptions (since 2022)

For PMHNPs:

• Transitioning to full independence via AB 890
• As of 2023: independent practice in group settings (if experienced)
• By 2026: full independent practice authority for qualified NPs
• Must obtain furnishing authority and DEA registration for controlled substances

Texas

For Psychiatrists:

• Must establish patient via synchronous audio-video exam
• Can prescribe controlled substances except for chronic pain management (not relevant to anxiety)
• Must check TX PMP before prescribing opioids, benzos, barbiturates, carisoprodol
• Member of IMLC (easier multi-state licensing)

For PMHNPs:

• Must have Prescriptive Authority Agreement with physician
• Cannot prescribe Schedule II in outpatient settings (hospital/hospice only)
• Can prescribe Schedule III–V (including benzos) under physician delegation
• One physician can supervise up to 7 NPs/PAs

Florida

For Psychiatrists:

• Can use FL Telehealth Provider Registration (for out-of-state clinicians) instead of full license
• Can prescribe Schedule II via telehealth for psychiatric conditions (unique state exception)
• Must check E-FORCSE PDMP before any Schedule II–V prescription and every 90 days
• Must obtain patient consent for telehealth (document in chart)

For PMHNPs:

• Must have physician supervisory protocol
• Schedule II limited to 7-day supply unless you’re a certified psychiatric nurse treating mental illness (then exception applies)
• One physician can supervise up to 4 NPs in Florida

New York

For Psychiatrists:

• Must have NY license (not in IMLC—requires full application)
• Must check I-STOP PMP before every Schedule II–IV prescription (includes all benzos)
• E-prescribing mandatory for all prescriptions (since 2016)
• Telehealth permitted without special restrictions

For PMHNPs:

• Independent practice after 3,600 hours (law made permanent in 2022)
• Before 3,600 hours: need collaborative agreement
• Once independent: prescribe controlled substances under own authority
• Same PDMP and e-prescribing rules as physicians

Pennsylvania

For Psychiatrists:

• Member of IMLC (streamlined licensing)
• Must check PA PDMP before each prescription of opioids or benzodiazepines (each refill)
• E-prescribing mandatory for controlled substances (since 2019)
• Telehealth permitted if standard of care met (video recommended for new patients)

For PMHNPs:

• Must have collaborative agreement (no independent practice yet)
• Schedule II: 30-day supply max, physician notified within 24 hours
• Schedule III–IV: 90-day supply max (means you can prescribe 90 days of benzos)
• One physician can collaborate with up to 4 NPs

Illinois

For Psychiatrists:

• Member of IMLC
• Must check IL PMP for Schedule II prescriptions (encouraged for all controlled drugs)
• Must have state controlled substance license (in addition to DEA)
• Audio-only telehealth permitted for mental health if necessary

For PMHNPs:

• Full Practice Authority available after 4,000 hours + training
• With FPA: prescribe Schedule III–V independently
• Schedule II narcotics (opioids) require physician consultation relationship first 5 years
• Schedule II non-narcotics (stimulants) and benzos: fully independent with FPA

State Comparison Table: Key Requirements at a Glance

Common Compliance Mistakes (and How to Avoid Them)

Mistake #1: Practicing Across State Lines Without Proper Licenses

The error: Treating patients in multiple states with only one state license.The fix: Obtain licenses in every state where your patients are located. Use IMLC pathways where available (TX, FL, PA, IL). For CA and NY, complete full applications.

Mistake #2: Skipping PDMP Checks

The error: Assuming you don’t need to check for ‘low-risk’ patients or refills.The fix: Integrate PDMP queries into your workflow. Most states require checks for every controlled prescription (NY, PA) or at regular intervals (CA, FL). Document every query.

Mistake #3: Using Audio-Only for New Controlled Substance Prescriptions

The error: Conducting initial evaluations via phone and prescribing benzos.The fix: Use video telehealth for new patient evaluations when prescribing controlled substances. Federal guidance strongly recommends live audio-video for controlled medication initiation.

Mistake #4: Not Documenting Telehealth Consent

The error: Jumping into treatment without explaining telehealth to patients.The fix: Document informed consent for telehealth services. Some states (FL, IL) specifically require this. Best practice everywhere: explain how telehealth works, limitations, and emergency procedures.

Mistake #5: Assuming PMHNP Scope Is the Same Everywhere

The error: Prescribing as you did in your home state when treating patients in other states.The fix: Know the rules for each state where you practice. Can’t prescribe Schedule II in Texas outpatient? Don’t try. Need a collaborative agreement in PA? Have it on file before seeing PA patients.

FAQ: Anxiety Prescribing Regulations

Q: Can I prescribe benzodiazepines via telehealth without ever seeing a patient in person?
A: Yes, under current federal rules (through December 31, 2025). The DEA’s COVID-era waiver allows prescribing Schedule II–V controlled substances via telemedicine without an in-person exam, provided you conduct a proper evaluation via audio-video and comply with state laws. This could change when the DEA issues final telemedicine rules—likely in 2025 or 2026.

Q: What’s the difference between Schedule II and Schedule IV in practical prescribing?
A: Most anxiety medications are Schedule IV (benzodiazepines like Xanax, Ativan, Klonopin). Schedule II includes stimulants (ADHD meds) and some stronger sedatives. Schedule II has stricter regulations: Texas NPs can’t prescribe it outpatient; Florida limits NPs to 7-day supplies for non-psychiatric uses; PA requires physician notification within 24 hours. For typical anxiety treatment, you’re dealing with Schedule IV, which has fewer restrictions but still requires PDMP checks.

Q: Do I need a DEA number for every state where I practice telehealth?
A: Yes. Your DEA registration must be in the state where you’re physically located when prescribing AND in any states where you maintain an office or practice location. For pure telehealth practice, you typically need DEA registration in each state where you’re licensed and treating patients. This is often misunderstood—check with your DEA registration specialist or compliance team.

Q: Can PMHNPs prescribe anxiety medications independently in all states?
A: No. It depends on the state. In NY (after 3,600 hours), IL (with FPA), and soon CA (2026), PMHNPs can practice and prescribe independently. In TX, FL, and PA, you need physician collaboration or supervision. The trend is toward independence (over half of states now allow full NP practice authority), but the largest states by population still have restrictions.

Q: What happens if federal telehealth prescribing rules change in 2026?
A: If the DEA reinstates an in-person visit requirement, telehealth anxiety practices will need to adapt—possibly by arranging affiliate clinics for initial exams, implementing hybrid care models, or using a special DEA telemedicine registration if created. The good news: patient demand and provider advocacy have already forced the DEA to reconsider strict limits three times. Any new rules will likely have transition periods and exceptions for mental health care.

Q: How often do I need to check the PDMP?
A: It varies by state. New York requires a check before every Schedule II–IV prescription. Pennsylvania requires a check each time you prescribe opioids or benzos (including refills). California requires checking within 24 hours of initial controlled prescription and at least every 4 months thereafter. Texas requires checking before first prescription of opioids/benzos. Know your state’s specific requirement—it’s one of the most commonly audited compliance items.

Q: Can I use a platform like Klarity Health to handle multi-state licensing and compliance?
A: Telehealth platforms like Klarity typically provide infrastructure support—EHR with integrated PDMP queries, EPCS e-prescribing, credentialing assistance, and compliance guidance for multi-state practice. However, you remain personally responsible for maintaining proper licenses, following prescribing laws, and practicing within your scope. The platform facilitates compliance; it doesn’t remove your obligation to know and follow the rules.

The Business Case: Why Getting This Right Matters

Here’s what providers often miss: regulatory compliance isn’t just about avoiding discipline—it’s about sustainable practice economics.

If you’re trying to build a multi-state telehealth anxiety practice on your own, you’ll face:

• $3,000–5,000/month in marketing spend to acquire patients through SEO, Google Ads, or directories
• 6–12 months before SEO generates meaningful patient flow
• $200–500+ true cost per qualified patient booked (after factoring in ad spend, agency fees, failed campaigns, and no-shows)
• Ongoing costs for EHR systems, e-prescribing software, PDMP integrations, credentialing, and compliance updates

Platforms like Klarity Health remove that upfront risk. Instead of gambling on marketing channels with no guaranteed return, you pay only when qualified patients book with you—a pay-per-appointment model similar to Zocdoc, but with the added value of:

• Patients pre-matched to your specialty and availability
• Built-in telehealth and prescribing infrastructure (EPCS, PDMP integration)
• No monthly subscription fees or wasted ad spend
• Both insurance and cash-pay patient flow
• Multi-state compliance support

The economic reality: A platform that handles patient acquisition, provides compliant infrastructure, and only charges when you see patients offers guaranteed ROI. You’re not spending $4,000/month hoping for results—you’re paying for actual appointments from qualified anxiety patients ready for treatment.

For psychiatrists and PMHNPs who want to focus on clinical care rather than marketing experiments and regulatory paperwork, that’s the smart choice.

Ready to Practice Anxiety Treatment Without the Compliance Headaches?

Klarity Health connects psychiatrists and PMHNPs with patients seeking anxiety treatment across multiple states—with built-in compliance infrastructure, qualified patient leads, and none of the upfront marketing risk.

Join a platform that handles:

• Multi-state credentialing support
• EPCS e-prescribing with PDMP integration
• Pre-screened patients matched to your availability
• Telehealth infrastructure that meets federal and state standards

You focus on treatment. We handle patient acquisition and compliance support.

Explore joining Klarity’s provider network →

Sources and Citations

1. DEA and HHS Extend Telemedicine Flexibilities through 2025 – Drug Enforcement Administration Press Release, November 15, 2024. www.dea.gov

2. 21 U.S.C. § 829(e) – Ryan Haight Online Pharmacy Consumer Protection Act – Cornell Law School Legal Information Institute (Current through 2025). www.law.cornell.edu/uscode/text/21/829

3. State Telehealth Policies: Online Prescribing – Center for Connected Health Policy, Updated January 9, 2026. www.cchpca.org/topic/online-prescribing

4. Florida Statute 456.47 – Telehealth Services – Florida Senate (2025 Edition). www.flsenate.gov/Laws/Statutes/2025/456.47

5. New York I-STOP/Prescription Monitoring Program Requirements – New York Department of Health (Effective August 27, 2013). health.ny.gov/professionals/narcotic/prescription_monitoring

Source:

• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=forward%20for%20telemedicine%2C%20DEA%20and,through%20the%20end%20of%202024
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Controlled%20Substance%20Act
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Note%20that%20the%20practice%20of,chapter%205%20of%20title%205
• https://www.flsenate.gov/Laws/Statutes/2025/456.47#:~:text=,services%20within%20the%20applicable%20scope
• https://healthweb-back.health.ny.gov/professionals/narcotic/prescription_monitoring/#:~:text=Effective%20August%2027%2C%202013%2C%20most,to%20view%20dispensed%20controlled%20substance
• https://www.bon.texas.gov/faqpracticeaprn.asp.html#:~:text=may%20prescribe%20Schedule%20II%20drugs%3F,care%20from%20a%20qualified%20hospice
• https://www.leg.state.fl.us/Statutes/index.cfm?Appmode=DisplayStatute&Search_String=&URL=0400-0499%2F0464%2FSections%2F0464.012.html#:~:text=893.03%20to%20a%207,formulary%20which%20it%20finds%20is
• https://www.flsenate.gov/Laws/Statutes/2025/456.47#:~:text=,is%20prescribed%20for%20the%20following
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Additionally%2C%20the%20rule%20shall%20state,addiction%20medicine%2C%20or%20palliative%20care
• https://www.cchpca.org/topic/online-prescribing/#:~:text=The%20Attorney%20General%20may%20issue,application%20for%20such%20special%20registration%E2%80%94